

## **Response to the Reviewer's comments**

We appreciate the reviewer's constructive comments. The reviewer has ably pointed out several important aspects relating to manuscript. In keeping with those concerns the manuscript is thoroughly revised. All the revisions are underlined in the text. Following is a point by point response to each of the comments. If there is still anything left, we will be happy to cooperate.

**Gong, Ze-Mao (BPG)** <z.m.gong@wjgnet.com>To

Sep 22 at 8:15 AM

Dear Dr. Sobia Manzoor,

I have seen your "**Answers to reviewer's comments**", but I did not see any about the reviewer's suggestion to response.

### **The Comments:**

1:In the final paragraph of the introduction, the authors point out that current HBV specific therapies are generally unable to eradicate HBV. The readers will be interesting in understanding the sustained virology response rate on current regimens. Please give a new Table to demonstrate 1-3 years post treatment sustained responses rates for each current therapy.

#### **Author's response:**

As per reviewer's suggestion, a new table (Table 1: Sustained Virology response rates (SVRs) of current therapies for HBV) has been incorporated on page number 62. Further, lines linked with the table 1 has been incorporated and underlined ( see "CURRENT THERAPIES FOR HBV" on page number 8).

2:In the conclusion, the authors seem to suggest that therapeutic vaccine plus NA will give a promising results in the future. **However, we cannot get a clear impression on reading the text. Please add information about the trial of NA in the Table 1 and give a brief but clear description on data that lead to this conclusion.**

#### **Author's response:**

We appreciate the reviewer's suggestion. Said information has been given in Table 5 "Nucleoside analogs in development for HBV" (as after incorporating a new table "Table 1", the order of tables have been changes) as well as explained and underlined in "Conclusion" on page 37.

## **Response to the Editor's comments**

We appreciate the editor's constructive comments. We are also thankful to editor for editing our review. Indeed his esteemed efforts contribute a lot to get the manuscript in finalized form.

The editor has ably pointed out several important aspects relating to manuscript. All the revisions are addressed in the text. Following is a point by point response to each of the comments. If there is still anything left, we will be happy to cooperate.

### **The Comments**

**Gong, Ze-Mao (BPG)** <z.m.gong@wjgnet.com> To

Dr.Sobia Manzoor

Sep 18 at 2:15 PM

Dear Dr. Sobia Manzoor,

I still found some questions in your revised files, such as:

1. Where is the title of Table 1?

Author's response:

We sincerely apologize for this mistake. Title of Table 1: Sustained Virology response rates (SVRs) of current therapies for HBV has been incorporated (see on page number 62)

2. Copyright need to sign again (correct format file in attachment)

Author's response:

A corrected copyright form that was received as an attachment by respected editor, has been provided (see attachment).

I hope that the manuscript will find suitable place in the coming issue of the journal. Thanks for your consideration.

Best regards

Sobia Manzoor, PhD

Assistant Professor

In-Charge Viral Hepatitis Research Group

HCB, Atta-ur-Rahman School of Applied Biosciences (ASAB)

National University of Sciences and Technology (NUST)

H-12, Islamabad 44000, Pakistan Office: +92 51 90856147

<http://www.nust.edu.pk/INSTITUTIONS/Schools/ASAB/Departments/HB/Faculty/Pages/Dr.-Sobia-Manzoor.aspx>

[https://www.researchgate.net/profile/Sobia\\_Manzoor2?ev=hdr\\_xprf](https://www.researchgate.net/profile/Sobia_Manzoor2?ev=hdr_xprf)